The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women

Joseph J. Carter(Fred Hutch Cancer Center), Laura A. Koutsky(University of Washington), G. C. Wipf(Penn State Milton S. Hershey Medical Center), Neil D. Christensen(Penn State Milton S. Hershey Medical Center), Sangkyu Lee(Penn State Milton S. Hershey Medical Center), Jane Kuypers(Cancer Research Center), Nancy B. Kiviat(Penn State Milton S. Hershey Medical Center), Denise A. Galloway(Penn State Milton S. Hershey Medical Center)
The Journal of Infectious Diseases
November 1, 1996
Cited by 331Open Access
Full Text

Abstract

To study the temporal relationship between serum antibody response and human papillomavirus type 16 (HPV-16) infection, a cohort of 325 university women were scheduled for examinations at 4-month intervals. At every examination, interviews were completed, cells were obtained for polymerase chain reaction-based testing and for Pap screening, and serum was obtained for testing with a HPV-16 capsid-capture ELISA. Seroreactivity was associated with detection of HPV-16 DNA and with increased numbers of sex partners. The median time to seroconversion was 8.3 months among women with incident HPV-16 infections. Within 16 months following HPV-16 DNA detection, 93.7% of women with prevalent and 67.1% of women with incident infections seroconverted. After seroconversion, antibody responses were maintained during follow-up among HPV-16 DNA-positive women. Women who seroconverted were 5.7 times (95% confidence interval = 2.4-13.4) more likely to have squamous intraepithelial lesions associated with the detection of HPV-16 DNA than were women who did not seroconvert.


Related Papers

No related papers found

Powered by citation graph analysis